Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review

Goglia, Umberto; Ferone, Diego; Sidoti, Marilena; Spaziante, Renato; Dadati, Patrizia; Ravetti, Jean Luis; Villa, Giuseppe; Bodei, Lisa; Paganelli, Giovanni; Minuto, Francesco; Giusti, Massimo

doi:10.1007/s11102-007-0038-6

Cited by 38 publications

(26 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequencies of primary sites are summarized in Fig. 1 (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 10...…”

Section: Resultsmentioning

confidence: 99%

Pituitary metastasis: a rare condition

Javanbakht

D’Apuzzo

Badie

et al. 2018

Endocrine Connections

135

View full text Add to dashboard Cite

Tumor metastasis to the pituitary gland is a rare, not well-documented and life-threatening condition associated with a shortened life span. A better understanding of its clinical manifestations could lead to earlier diagnosis, appropriate therapy and potentially improving quality of life. Therefore, we retrospectively studied the charts of patients with pituitary metastases who were treated at the City of Hope National Medical Center (Duarte, CA) from 1984 to 2018. We reviewed and analyzed tumor origin, primary pituitary clinical manifestation, duration between primary tumor diagnosis and pituitary metastasis, type of treatment and patient survival. A total of 11 patients were identified with a mean age of 59.2 years and median survival following the diagnosis of metastasis of 10 months. Breast cancer and lymphoma were the most common primary origins in these cases, and diabetes insipidus and panhypopituitarism were the most common clinical manifestations of their metastasis. We also compared our results with reports in the literature published between 1957 and 2018. A total 289 patients with pituitary metastasis have been reported in the literature. Breast cancer was the most frequent primary origin of the metastasis, and visual symptoms were the most common primary manifestation. The posterior part of the pituitary is more susceptible than the anterior to metastasis. Pituitary metastasis may occur as a consequence of successful primary tumor treatment prolonging the chance of seeding. Future studies are needed to determine the molecular mechanism of metastasis to the pituitary.

show abstract

Section: Resultsmentioning

confidence: 99%

Pituitary metastasis: a rare condition

Javanbakht

D’Apuzzo

Badie

et al. 2018

Endocrine Connections

135

View full text Add to dashboard Cite

show abstract

“…Moreover, pituitary uptake of 68Ga-DOTATATE or other radiolabeled somatostatin analogues has been demonstrated on PET/ CT (159,160), suggesting that PPRT could be an option for pituitary tumours, as described for neuroendocrine tumours (161,162), including pituitary metastasis (163). Fourteen patients with aggressive pituitary tumours (lactotroph (n = 5), gonadotroph (n = 3), corticotroph (n = 2) somatotroph (n = 3) and mixed somatolactotroph (n = 1)) treated with PPRT are reported in the literature.…”

Section: Peptide Receptor Radionuclide Therapy (Pprt)mentioning

confidence: 97%

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Raverot

Burman

McCormack

et al. 2018

European Journal of Endocrinology

456

583

View full text Add to dashboard Cite

Background: Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The present European Society of Endocrinology (ESE) guideline aims to provide clinical guidance on diagnosis, treatment and follow-up in aggressive pituitary tumours and carcinomas. Methods: We decided upfront, while acknowledging that literature on aggressive pituitary tumours and carcinomas is scarce, to systematically review the literature according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. The review focused primarily on first-and second-line treatment in aggressive pituitary tumours and carcinomas. We included 14 single-arm cohort studies (total number of patients = 116) most on temozolomide treatment (n = 11 studies, total number of patients = 106). A positive treatment effect was seen in 47% (95% CI: 36-58%) of temozolomide treated. Data from the recently performed ESE survey on aggressive pituitary tumours and carcinomas (165 patients) were also used as backbone for the guideline. In patients responding to first-line temozolomide, we suggest continuing treatment for at least 6 months in total. Furthermore, the guideline offers recommendations for patients who recurred after temozolomide treatment, for those who did not respond to temozolomide and for patients with systemic metastasis.

show abstract

“…Similarly, conflicting results using [ 111 In]-DTPA-octreotide in pituitary adenomas were reported [103]. Few case-report studies demonstrated the efficacy and safety of radiolabeled SST-analogs in pituitary metastasis in a patient with NET [104] and in a case of relapsed prolactin-secreting giant pituitary adenoma [105]. …”

Section: Radioactive Somatostatin Analogs For Imaging and Therapymentioning

confidence: 99%

Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm

Barbieri

Bajetto

Pattarozzi

et al. 2013

International Journal of Peptides

108

View full text Add to dashboard Cite

Peptide receptors involved in pathophysiological processes represent promising therapeutic targets. Neuropeptide somatostatin (SST) is produced by specialized cells in a large number of human organs and tissues. SST primarily acts as inhibitor of endocrine and exocrine secretion via the activation of five G-protein-coupled receptors, named sst1–5, while in central nervous system, SST acts as a neurotransmitter/neuromodulator, regulating locomotory and cognitive functions. Critical points of SST/SST receptor biology, such as signaling pathways of individual receptor subtypes, homo- and heterodimerization, trafficking, and cross-talk with growth factor receptors, have been extensively studied, although functions associated with several pathological conditions, including cancer, are still not completely unraveled. Importantly, SST exerts antiproliferative and antiangiogenic effects on cancer cells in vitro, and on experimental tumors in vivo. Moreover, SST agonists are clinically effective as antitumor agents for pituitary adenomas and gastro-pancreatic neuroendocrine tumors. However, SST receptors being expressed by tumor cells of various tumor histotypes, their pharmacological use is potentially extendible to other cancer types, although to date no significant results have been obtained. In this paper the most recent findings on the expression and functional roles of SST and SST receptors in tumor cells are discussed.

show abstract

Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review

Cited by 38 publications

References 27 publications

Pituitary metastasis: a rare condition

Pituitary metastasis: a rare condition

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm

Contact Info

Product

Resources

About